KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Interest Expenses (2016 - 2020)

Nektar Therapeutics has reported Interest Expenses over the past 11 years, most recently at $647000.0 for Q2 2020.

  • Quarterly results put Interest Expenses at $647000.0 for Q2 2020, down 87.63% from a year ago — trailing twelve months through Mar 2021 was $647000.0 (down 97.1% YoY), and the annual figure for FY2020 was $6.9 million, down 67.85%.
  • Interest Expenses for Q2 2020 was $647000.0 at Nektar Therapeutics, down from $6.2 million in the prior quarter.
  • Over the last five years, Interest Expenses for NKTR hit a ceiling of $6.2 million in Q1 2020 and a floor of $647000.0 in Q2 2020.
  • Median Interest Expenses over the past 5 years was $5.4 million (2018), compared with a mean of $5.2 million.
  • Biggest five-year swings in Interest Expenses: soared 36.64% in 2016 and later plummeted 87.63% in 2020.
  • Nektar Therapeutics' Interest Expenses stood at $5.6 million in 2016, then increased by 1.5% to $5.6 million in 2017, then fell by 3.87% to $5.4 million in 2018, then grew by 0.24% to $5.4 million in 2019, then tumbled by 88.08% to $647000.0 in 2020.
  • The last three reported values for Interest Expenses were $647000.0 (Q2 2020), $6.2 million (Q1 2020), and $5.4 million (Q4 2019) per Business Quant data.